Company overview unavailable
$271.22
+$0.54 (+0.20%)Last close · 2026-09-25
Free AI rating for JNJ
See QuantAdvisor's buy/sell/hold call and the reasoning — no account needed.
Price history
Daily closing prices for JNJ.
+$12.71 (+4.92%) over the last 3m
Related news
Recent coverage of JNJ.

Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.
Yahoo · 1d ago

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.
SeekingAlpha · 1d ago

Johnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data suggest TECVAYLI plus DARZALEX FASPRO could align patient mortality risk with that of the general population. CARVYKTI results highlight treatment-free remissions lasting five years in relapsed or refractory multiple myeloma, while TREMFYA data support an axial psoriatic arthritis label...
Yahoo · 1d ago

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
Yahoo · 1d ago

At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
Yahoo · 2d ago

The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
Yahoo · 2d ago

Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.
ChartMill · 2d ago

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
Yahoo · 2d ago
Key statistics
Company fundamentals are temporarily unavailable.
StockTwits chatter
What traders are saying on StockTwits right now
No StockTwits chatter available right now.
Source: StockTwits
Community
Recent posts mentioning JNJ.
Sign in to join the QuantAdvisor conversation on JNJ — post your take, like and follow.
Data may be delayed. For research, not financial advice.
© 2026 QuantAdvisor. All rights reserved.